These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2443920)

  • 1. Peptide hormones, serotonin, and other cell differentiation markers in benign hyperplasia and in carcinoma of the prostate.
    Abrahamsson PA; Alumets J; Wadström LB; Falkmer S; Grimelius L
    Prog Clin Biol Res; 1987; 243A():489-502. PubMed ID: 2443920
    [No Abstract]   [Full Text] [Related]  

  • 2. Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy.
    Geller J; Albert J; Nachtsheim D; Loza D; Lippman S
    Prog Clin Biol Res; 1979; 33():103-11. PubMed ID: 93747
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate.
    Abrahamsson PA; Wadström LB; Alumets J; Falkmer S; Grimelius L
    Pathol Res Pract; 1987 Jun; 182(3):298-307. PubMed ID: 2442732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG; Aiad HA; Sultan SM
    APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-cadherin: expression of the epithelial cell-cell-adhesion molecule in prostatic carcinoma and normal prostate.
    Rembrink K; Otto T; Goepel M; Enzawi SM; Rübben H
    Investig Urol (Berl); 1994; 5():24-7. PubMed ID: 7536522
    [No Abstract]   [Full Text] [Related]  

  • 7. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidental carcinoma of the prostate].
    Vecchioli Scaldazza C; Garritano A; Rossi G; Albini C
    Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):37-42. PubMed ID: 2469128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Various immunohistochemical markers of precancer and variants of prostate cancer].
    Romanenko AM; Vorob'eva LR
    Arkh Patol; 1995; 57(4):38-41. PubMed ID: 8526754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
    Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
    J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical spindle cell lesions of the prostate.
    Têtu B; Ro JY; Ayala AG; Srigley JR; Bégin LR; Bostwick DG
    Semin Diagn Pathol; 1988 Aug; 5(3):284-93. PubMed ID: 2459753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological aspects of prostate cancer and benign nodular hyperplasia.
    Wernert N; Bieroff E; Hügel A
    Anticancer Res; 1997; 17(4B):2907-10. PubMed ID: 9329560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate.
    Botticelli AR
    Pathologica; 1994 Apr; 86(2):128-41. PubMed ID: 7524011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
    Dema A; Tudose N
    Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma.
    Mydlo JH; Michaeli J; Heston WD; Fair WR
    Prostate; 1988; 13(3):241-7. PubMed ID: 2463616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
    Mohler JL; Chen Y; Hamil K; Hall SH; Cidlowski JA; Wilson EM; French FS; Sar M
    Clin Cancer Res; 1996 May; 2(5):889-95. PubMed ID: 9816246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of epidermal growth factor in human benign prostatic hyperplasia and prostatic carcinoma and its prognostic significance.
    Shaikh N; Lai L; McLoughlin J; Clark D; Williams G
    Anticancer Res; 1990; 10(4):873-4. PubMed ID: 1696447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoreactivity of ubiquitin in human prostate gland.
    Bataineh ZM; Habbal O
    Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.